Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
Purpose The aim of the present study was to evaluate changes of best corrected visual acuity (BCVA), retinal nerve fiber layer thickness (RNFL), total macular volume (TMV), intraocular pressure (IOP) and central retinal thickness (CRT) after intravitreal injection of ranibizumab, bevacizumab and afl...
Gespeichert in:
| Veröffentlicht in: | International ophthalmology 2023-01, Vol.43 (1), p.13-25 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 25 |
|---|---|
| container_issue | 1 |
| container_start_page | 13 |
| container_title | International ophthalmology |
| container_volume | 43 |
| creator | Lüke, Jan Niklas Alquoqa, Hamdi Alsamman, Ahmad Aljabary, Bayan Schaub, F. Heindl, L. M. |
| description | Purpose
The aim of the present study was to evaluate changes of best corrected visual acuity (BCVA), retinal nerve fiber layer thickness (RNFL), total macular volume (TMV), intraocular pressure (IOP) and central retinal thickness (CRT) after intravitreal injection of ranibizumab, bevacizumab and aflibercept in patients with neovascular age-related macular degeneration (nAMD) in a clinical real world setting.
Methods
In a retrospective clinical study design, 120 patients (80 women and 40 men) were analyzed after being diagnosed with nAMD within 8 years (2010–2018). Every patient received at least 6 anti-VEGF injections in a Pro-Re-Nata or Treat-and-Extend regimen. OCT parameters (RNFL, TMV, CRT) and visual acuity (BCVA) were assessed at first diagnosis, at treatment day and during the course.
Results
Intraretinal fluid was reduced significantly in a magnitude of 88–64 µm (CRT) and 0.75–0.55 mm
3
(TMV). Apart from a significant reduction immediately after the therapy start (post-3 injections) with ranibizumab (− 1.4 µm,
p
= 0.03), RNFL thickness remained constant. A slight improvement in visual acuity of 0.06 logMAR could initially be observed. If further injections were required, only stabilization was achieved compared to baseline visual acuity.
Conclusion
The changes of OCT parameters CRT, TMV, and RNFL as well as the stabilization of functional results (BCVA) as illustrated in this study comparing effects of different anti-VEGF-agents provide evidence for the transferability of former results to a clinical real-world setting. |
| doi_str_mv | 10.1007/s10792-022-02383-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9902313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2685033619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-907731a35b0a714464436d1c54f19b6320b7e27ab782fa3f647cfa2220039e43</originalsourceid><addsrcrecordid>eNp9kUtv3CAUhVHVqnm0f6CLCqmbbtwAF8OwqRRN86iUKlI06hZde_CEyGOmgCfKvj-8OJMmaRdZoIu43z1wOIR84OwLZ0wfJc60ERUT04IZVOoV2ee1hkooYK-f7ffIQUo3jDGjjXpL9qDWM16bep_8vnI5hrRxbfZbR3HA_i75RENHL-cLusGIa5ddTBS7UqgfcsStz9FhX-jsq58nZ6fl-No3PofC-YEOLmwxtWOPkR7_-FZUsndDvu8hnUar2xD7JU0uZz-s3pE3HfbJvX-oh2RxerKYn1cXl2ff58cXVSu1zJVhWgNHqBuGmkuppAS15G0tO24aBYI12gmNjZ6JDqFTUrcdCiEYA-MkHJKvO9nN2KzdsnWTl95uol9jvLMBvf23M_hruwpba0z5Xw5F4PODQAy_RpeyXfvUur7H4nhMVqhZzQAUNwX99B96E8ZYfrdQxYXUAFoVSuyotmSQouseH8OZnTK2u4xtydjeZ2ynoY_PbTyO_A21ALADUmkNKxef7n5B9g-sKbNu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2773473376</pqid></control><display><type>article</type><title>Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Lüke, Jan Niklas ; Alquoqa, Hamdi ; Alsamman, Ahmad ; Aljabary, Bayan ; Schaub, F. ; Heindl, L. M.</creator><creatorcontrib>Lüke, Jan Niklas ; Alquoqa, Hamdi ; Alsamman, Ahmad ; Aljabary, Bayan ; Schaub, F. ; Heindl, L. M.</creatorcontrib><description>Purpose
The aim of the present study was to evaluate changes of best corrected visual acuity (BCVA), retinal nerve fiber layer thickness (RNFL), total macular volume (TMV), intraocular pressure (IOP) and central retinal thickness (CRT) after intravitreal injection of ranibizumab, bevacizumab and aflibercept in patients with neovascular age-related macular degeneration (nAMD) in a clinical real world setting.
Methods
In a retrospective clinical study design, 120 patients (80 women and 40 men) were analyzed after being diagnosed with nAMD within 8 years (2010–2018). Every patient received at least 6 anti-VEGF injections in a Pro-Re-Nata or Treat-and-Extend regimen. OCT parameters (RNFL, TMV, CRT) and visual acuity (BCVA) were assessed at first diagnosis, at treatment day and during the course.
Results
Intraretinal fluid was reduced significantly in a magnitude of 88–64 µm (CRT) and 0.75–0.55 mm
3
(TMV). Apart from a significant reduction immediately after the therapy start (post-3 injections) with ranibizumab (− 1.4 µm,
p
= 0.03), RNFL thickness remained constant. A slight improvement in visual acuity of 0.06 logMAR could initially be observed. If further injections were required, only stabilization was achieved compared to baseline visual acuity.
Conclusion
The changes of OCT parameters CRT, TMV, and RNFL as well as the stabilization of functional results (BCVA) as illustrated in this study comparing effects of different anti-VEGF-agents provide evidence for the transferability of former results to a clinical real-world setting.</description><identifier>ISSN: 1573-2630</identifier><identifier>ISSN: 0165-5701</identifier><identifier>EISSN: 1573-2630</identifier><identifier>DOI: 10.1007/s10792-022-02383-6</identifier><identifier>PMID: 35781595</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Acuity ; Age ; Age related diseases ; Angiogenesis Inhibitors ; Bevacizumab ; Eye diseases ; Female ; Humans ; Intraocular pressure ; Intravitreal Injections ; Macular degeneration ; Male ; Medicine ; Medicine & Public Health ; Ophthalmology ; Original Paper ; Parameters ; Patients ; Ranibizumab ; Recombinant Fusion Proteins ; Retina ; Retrospective Studies ; Stabilization ; Thickness ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A ; Visual Acuity ; Visual observation ; Wet Macular Degeneration - diagnosis ; Wet Macular Degeneration - drug therapy</subject><ispartof>International ophthalmology, 2023-01, Vol.43 (1), p.13-25</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-907731a35b0a714464436d1c54f19b6320b7e27ab782fa3f647cfa2220039e43</citedby><cites>FETCH-LOGICAL-c474t-907731a35b0a714464436d1c54f19b6320b7e27ab782fa3f647cfa2220039e43</cites><orcidid>0000-0001-7131-7652</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10792-022-02383-6$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10792-022-02383-6$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35781595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lüke, Jan Niklas</creatorcontrib><creatorcontrib>Alquoqa, Hamdi</creatorcontrib><creatorcontrib>Alsamman, Ahmad</creatorcontrib><creatorcontrib>Aljabary, Bayan</creatorcontrib><creatorcontrib>Schaub, F.</creatorcontrib><creatorcontrib>Heindl, L. M.</creatorcontrib><title>Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting</title><title>International ophthalmology</title><addtitle>Int Ophthalmol</addtitle><addtitle>Int Ophthalmol</addtitle><description>Purpose
The aim of the present study was to evaluate changes of best corrected visual acuity (BCVA), retinal nerve fiber layer thickness (RNFL), total macular volume (TMV), intraocular pressure (IOP) and central retinal thickness (CRT) after intravitreal injection of ranibizumab, bevacizumab and aflibercept in patients with neovascular age-related macular degeneration (nAMD) in a clinical real world setting.
Methods
In a retrospective clinical study design, 120 patients (80 women and 40 men) were analyzed after being diagnosed with nAMD within 8 years (2010–2018). Every patient received at least 6 anti-VEGF injections in a Pro-Re-Nata or Treat-and-Extend regimen. OCT parameters (RNFL, TMV, CRT) and visual acuity (BCVA) were assessed at first diagnosis, at treatment day and during the course.
Results
Intraretinal fluid was reduced significantly in a magnitude of 88–64 µm (CRT) and 0.75–0.55 mm
3
(TMV). Apart from a significant reduction immediately after the therapy start (post-3 injections) with ranibizumab (− 1.4 µm,
p
= 0.03), RNFL thickness remained constant. A slight improvement in visual acuity of 0.06 logMAR could initially be observed. If further injections were required, only stabilization was achieved compared to baseline visual acuity.
Conclusion
The changes of OCT parameters CRT, TMV, and RNFL as well as the stabilization of functional results (BCVA) as illustrated in this study comparing effects of different anti-VEGF-agents provide evidence for the transferability of former results to a clinical real-world setting.</description><subject>Acuity</subject><subject>Age</subject><subject>Age related diseases</subject><subject>Angiogenesis Inhibitors</subject><subject>Bevacizumab</subject><subject>Eye diseases</subject><subject>Female</subject><subject>Humans</subject><subject>Intraocular pressure</subject><subject>Intravitreal Injections</subject><subject>Macular degeneration</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Original Paper</subject><subject>Parameters</subject><subject>Patients</subject><subject>Ranibizumab</subject><subject>Recombinant Fusion Proteins</subject><subject>Retina</subject><subject>Retrospective Studies</subject><subject>Stabilization</subject><subject>Thickness</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A</subject><subject>Visual Acuity</subject><subject>Visual observation</subject><subject>Wet Macular Degeneration - diagnosis</subject><subject>Wet Macular Degeneration - drug therapy</subject><issn>1573-2630</issn><issn>0165-5701</issn><issn>1573-2630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtv3CAUhVHVqnm0f6CLCqmbbtwAF8OwqRRN86iUKlI06hZde_CEyGOmgCfKvj-8OJMmaRdZoIu43z1wOIR84OwLZ0wfJc60ERUT04IZVOoV2ee1hkooYK-f7ffIQUo3jDGjjXpL9qDWM16bep_8vnI5hrRxbfZbR3HA_i75RENHL-cLusGIa5ddTBS7UqgfcsStz9FhX-jsq58nZ6fl-No3PofC-YEOLmwxtWOPkR7_-FZUsndDvu8hnUar2xD7JU0uZz-s3pE3HfbJvX-oh2RxerKYn1cXl2ff58cXVSu1zJVhWgNHqBuGmkuppAS15G0tO24aBYI12gmNjZ6JDqFTUrcdCiEYA-MkHJKvO9nN2KzdsnWTl95uol9jvLMBvf23M_hruwpba0z5Xw5F4PODQAy_RpeyXfvUur7H4nhMVqhZzQAUNwX99B96E8ZYfrdQxYXUAFoVSuyotmSQouseH8OZnTK2u4xtydjeZ2ynoY_PbTyO_A21ALADUmkNKxef7n5B9g-sKbNu</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Lüke, Jan Niklas</creator><creator>Alquoqa, Hamdi</creator><creator>Alsamman, Ahmad</creator><creator>Aljabary, Bayan</creator><creator>Schaub, F.</creator><creator>Heindl, L. M.</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7131-7652</orcidid></search><sort><creationdate>20230101</creationdate><title>Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting</title><author>Lüke, Jan Niklas ; Alquoqa, Hamdi ; Alsamman, Ahmad ; Aljabary, Bayan ; Schaub, F. ; Heindl, L. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-907731a35b0a714464436d1c54f19b6320b7e27ab782fa3f647cfa2220039e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acuity</topic><topic>Age</topic><topic>Age related diseases</topic><topic>Angiogenesis Inhibitors</topic><topic>Bevacizumab</topic><topic>Eye diseases</topic><topic>Female</topic><topic>Humans</topic><topic>Intraocular pressure</topic><topic>Intravitreal Injections</topic><topic>Macular degeneration</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Original Paper</topic><topic>Parameters</topic><topic>Patients</topic><topic>Ranibizumab</topic><topic>Recombinant Fusion Proteins</topic><topic>Retina</topic><topic>Retrospective Studies</topic><topic>Stabilization</topic><topic>Thickness</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A</topic><topic>Visual Acuity</topic><topic>Visual observation</topic><topic>Wet Macular Degeneration - diagnosis</topic><topic>Wet Macular Degeneration - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lüke, Jan Niklas</creatorcontrib><creatorcontrib>Alquoqa, Hamdi</creatorcontrib><creatorcontrib>Alsamman, Ahmad</creatorcontrib><creatorcontrib>Aljabary, Bayan</creatorcontrib><creatorcontrib>Schaub, F.</creatorcontrib><creatorcontrib>Heindl, L. M.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lüke, Jan Niklas</au><au>Alquoqa, Hamdi</au><au>Alsamman, Ahmad</au><au>Aljabary, Bayan</au><au>Schaub, F.</au><au>Heindl, L. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting</atitle><jtitle>International ophthalmology</jtitle><stitle>Int Ophthalmol</stitle><addtitle>Int Ophthalmol</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>43</volume><issue>1</issue><spage>13</spage><epage>25</epage><pages>13-25</pages><issn>1573-2630</issn><issn>0165-5701</issn><eissn>1573-2630</eissn><abstract>Purpose
The aim of the present study was to evaluate changes of best corrected visual acuity (BCVA), retinal nerve fiber layer thickness (RNFL), total macular volume (TMV), intraocular pressure (IOP) and central retinal thickness (CRT) after intravitreal injection of ranibizumab, bevacizumab and aflibercept in patients with neovascular age-related macular degeneration (nAMD) in a clinical real world setting.
Methods
In a retrospective clinical study design, 120 patients (80 women and 40 men) were analyzed after being diagnosed with nAMD within 8 years (2010–2018). Every patient received at least 6 anti-VEGF injections in a Pro-Re-Nata or Treat-and-Extend regimen. OCT parameters (RNFL, TMV, CRT) and visual acuity (BCVA) were assessed at first diagnosis, at treatment day and during the course.
Results
Intraretinal fluid was reduced significantly in a magnitude of 88–64 µm (CRT) and 0.75–0.55 mm
3
(TMV). Apart from a significant reduction immediately after the therapy start (post-3 injections) with ranibizumab (− 1.4 µm,
p
= 0.03), RNFL thickness remained constant. A slight improvement in visual acuity of 0.06 logMAR could initially be observed. If further injections were required, only stabilization was achieved compared to baseline visual acuity.
Conclusion
The changes of OCT parameters CRT, TMV, and RNFL as well as the stabilization of functional results (BCVA) as illustrated in this study comparing effects of different anti-VEGF-agents provide evidence for the transferability of former results to a clinical real-world setting.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>35781595</pmid><doi>10.1007/s10792-022-02383-6</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-7131-7652</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1573-2630 |
| ispartof | International ophthalmology, 2023-01, Vol.43 (1), p.13-25 |
| issn | 1573-2630 0165-5701 1573-2630 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9902313 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Acuity Age Age related diseases Angiogenesis Inhibitors Bevacizumab Eye diseases Female Humans Intraocular pressure Intravitreal Injections Macular degeneration Male Medicine Medicine & Public Health Ophthalmology Original Paper Parameters Patients Ranibizumab Recombinant Fusion Proteins Retina Retrospective Studies Stabilization Thickness Tomography, Optical Coherence Treatment Outcome Vascular endothelial growth factor Vascular Endothelial Growth Factor A Visual Acuity Visual observation Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy |
| title | Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T18%3A55%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retrospective%20analysis%20of%20OCT%20parameters%20after%20intravitreal%20anti-VEGF%20inhibitors%20in%20neovascular%20AMD%20patients%20in%20a%20real-world%20setting&rft.jtitle=International%20ophthalmology&rft.au=L%C3%BCke,%20Jan%20Niklas&rft.date=2023-01-01&rft.volume=43&rft.issue=1&rft.spage=13&rft.epage=25&rft.pages=13-25&rft.issn=1573-2630&rft.eissn=1573-2630&rft_id=info:doi/10.1007/s10792-022-02383-6&rft_dat=%3Cproquest_pubme%3E2685033619%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2773473376&rft_id=info:pmid/35781595&rfr_iscdi=true |